Healios KK
TSE:4593
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
115
259
|
| Price Target |
|
We'll email you a reminder when the closing price reaches JPY.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Healios KK
Healios KK
PP&E Net
Healios KK
PP&E Net Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | PP&E Net | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Healios KK
TSE:4593
|
PP&E Net
¥474m
|
CAGR 3-Years
-23%
|
CAGR 5-Years
20%
|
CAGR 10-Years
N/A
|
|
|
GNI Group Ltd
TSE:2160
|
PP&E Net
¥6.9B
|
CAGR 3-Years
27%
|
CAGR 5-Years
23%
|
CAGR 10-Years
40%
|
|
|
PeptiDream Inc
TSE:4587
|
PP&E Net
¥17.2B
|
CAGR 3-Years
39%
|
CAGR 5-Years
24%
|
CAGR 10-Years
59%
|
|
|
Takara Bio Inc
TSE:4974
|
PP&E Net
¥50.1B
|
CAGR 3-Years
15%
|
CAGR 5-Years
18%
|
CAGR 10-Years
11%
|
|
|
Pharma Foods International Co Ltd
TSE:2929
|
PP&E Net
¥4.6B
|
CAGR 3-Years
37%
|
CAGR 5-Years
37%
|
CAGR 10-Years
21%
|
|
|
C
|
Cuorips Inc
TSE:4894
|
PP&E Net
¥514.1m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Healios KK
Glance View
Healios KK engages in the research, development, and sale of cellular and regenerative medicine. The company is headquartered in Chiyoda-Ku, Tokyo-To and currently employs 116 full-time employees. The company went IPO on 2015-06-16. is a Japan-based company mainly engaged in research and development of pharmaceutical products. The firm has compound pharmaceutical products line and induced pluripotent stem cell (iPSC) regenerative medicine product line. The compound pharmaceutical product line contains HLM0021, HLM0022 and HLM0023. The products are ophthalmological surgery adjuvants, mainly contain brilliant blue G-250 (BBG250) which help capsule temporarily safely stained to protect the inner limiting membranes and lens during surgery of vitreous and cataract. The iPSC regenerative medicine product line contains HLCR011 and HLCR012. The products are in the preclinical testing and preparation for trial in Japan, which are candidate of regenerative medicine products. The products are iPS cell derived retinal pigment epithelium (RPE) cell suspension and sheet developed in Japan, United States and Europe.
See Also
What is Healios KK's PP&E Net?
PP&E Net
474m
JPY
Based on the financial report for Sep 30, 2024, Healios KK's PP&E Net amounts to 474m JPY.
What is Healios KK's PP&E Net growth rate?
PP&E Net CAGR 5Y
20%
Over the last year, the PP&E Net growth was -36%. The average annual PP&E Net growth rates for Healios KK have been -23% over the past three years , 20% over the past five years .
You don't have any saved screeners yet
